52 results about "Systemic inflammation" patented technology

The invention discloses chiral ionizable lipid nanoparticles and a preparation method thereof, and belongs to the technical field of biomedical materials. The chiral ionizable lipid nanoparticle comprises chiral amino acid derived lipid, ionizable lipid, auxiliary lipid, cholesterol, a phospholipid polyethylene glycol derivative and an RNA (Ribonucleic Acid) drug, the preparation method comprises the following steps: dissolving chiral amino acid derived lipid in methanol, respectively dissolving ionizable lipid, auxiliary lipid, cholesterol and phospholipid polyethylene glycol derivative in ethanol, and mixing to obtain a total lipid organic phase; dissolving an RNA drug in DEPC water to obtain an RNA aqueous solution, and mixing the RNA aqueous solution with an acidic buffer solution to obtain an RNA aqueous phase; quickly mixing the total lipid organic phase and the RNA water phase, and standing and incubating; adding the mixed solution into a 3500 Da dialysis bag, taking 1 * phosphate buffer solution (PBS, pH = 7.4) as an external water phase, and dialyzing to obtain the chiral ionizable lipid nanoparticles. The lipid nanoparticles provided by the invention can enhance the RNA uptake efficiency, and have good application prospects in the treatment of systemic inflammation and other diseases.

The invention discloses a bone defect repair material suitability prediction method based on deep learning, and the method comprises the steps: carrying out the overlapping and uniform partitioning of a bone defect region and a host bone region in three-dimensional CT image data, carrying out the position coding and feature extraction of a plurality of sub-blocks through a three-dimensional visual Transform model of multi-scale position coding, and obtaining the anatomical and functional features; calculating a bone metabolism activity score and a systemic inflammation score based on blood detection data, and then constructing pathophysiological features; performing multi-round interaction on the anatomical and functional features, the pathophysiological features, the parameter data and the multidirectional multi-head cross attention layer, in each round, selecting one modal feature as a query vector, and selecting any modal feature in the rest modal features as a key vector and a value vector; and fusing the interaction features of each round, and determining the suitability score and the risk level of the bone repair material by combining the attention weight and the bone metabolism activity score in the multidirectional multi-head cross attention layer.

The application discloses a method for preparing cell-derived exosomes and products and applications thereof, and the method comprises the following steps: co-culturing immune-activated programmable cells with a stimulating agent with immune-activation effect, and collecting the cell-derived exosomes with immune activity by a natural secretion collection method or an artificial extrusion collection method. The application has safe and controllable local immune activation, and the immune activation strategy based on the exosomes fully overcomes the safety bottleneck of traditional live bacterial preparations in tumor treatment. By replacing live bacteria with engineered exosomes, not only potential risks such as systemic inflammatory response and infection are effectively avoided, but also the local controllability of immune stimulation signals is ensured, the precise activation and directional regulation of tumor region immune cells are realized, the tumor microenvironment is reshaped, the anti-tumor effect is strengthened, and the broad-spectrum cross-tumor potential is verified across models.

The invention relates to an application of a nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases, the nano antibody is an NB21 nano antibody, and the NB21 nano antibody has an amino acid sequence as shown in SEQ ID No.12. The invention also relates to an application of the nano antibody for blocking RSPO1-LGR4 effect in preparation of a medicine for treating cardiovascular diseases. The antibody can specifically block a Wnt / beta-catenin pathway, effectively inhibit expression of proinflammatory factors and relieve inflammatory response of heart tissues, so that occurrence and development of cardiovascular diseases are intervened. The nano antibody has significant advantages in the aspects of intervention accuracy, conversion reliability and the like, and preclinical results show that the nano antibody can improve occurrence and development of ischemic cardiomyopathy; the pharmaceutical composition can be used for treating heart failure, myocarditis and adriamycin cardiomyopathy, can be expanded to systemic inflammatory diseases, realizes the trans-boundary application of one drug with multiple targets, fully verifies the anti-inflammatory effectiveness and safety through in-vivo and in-vitro experimental data, provides new targets, diagnostic tools and accurate intervention schemes for diagnosis and treatment of cardiovascular diseases and systemic inflammatory diseases, and has wide application prospects. The obvious scientific innovation significance and clinical transformation value are realized.

The invention discloses a method for improving the quality of ganoderma lucidum mushroom residues through synergistic fermentation of bacteria and enzymes and application of the method. According to the method disclosed by the invention, cellulase, beta-galactosidase and xylanase with proper concentrations and lactobacillus plantarum, bacillus subtilis and saccharomyces cerevisiae with proper proportions are adopted, and enzymes and bacteria are mutually cooperated, so that the characteristics of the raw materials are well balanced, the finally prepared ganoderma lucidum mushroom bran is high in protein content and low in fiber content, and the nutritional value of a feed is improved; the total amount of amino acids and essential amino acids are remarkably increased, and the feed protein quality can be improved; the rumen dry matter digestibility and energy metabolites are remarkably improved, and ruminant absorption and utilization are facilitated; the ganoderma lucidum mushroom bran fermented feed is added into the daily ration, so that the daily gain, the carcass rate and the dressing percentage of fed animals can be remarkably improved, the levels of serum GLU, TG, ALT and AST are reduced, the expression of key inflammatory cytokines (IL-1beta and IL-6) is inhibited, and the ganoderma lucidum mushroom bran fermented feed has the comprehensive effects of regulating glycolipid metabolism and relieving liver load and systemic inflammation, so that the immune function of animal bodies is improved.

The application provides a marker for diagnosing systemic inflammation and application, the marker comprising ADGRE3 mRNA or ADGRE3 protein, or ADGRE3 mRNA fragment, ADGRE3 protein fragment, and the marker content in samples of systemic inflammation patients and healthy people has significant difference, and the marker diagnosis has high sensitivity and specificity in clinical verification, therefore, by detecting the ADGRE3 mRNA transcription level or the ADGRE3 protein expression level in the individual sample, systemic inflammation can be accurately diagnosed.Compared with existing inflammation markers, ADGRE3 mRNA and ADGRE3 protein have higher sensitivity and specificity in diagnosing systemic inflammation.

The present invention relates to the field of diagnostics. Specifically, the present invention relates to a method for assessing systemic inflammation in a subject exhibiting symptoms of systemic inflammation, the method comprising: a) determining the amount of biomarkers from a set of biomarkers selected from the group consisting of: i) a first set of biomarkers comprising POMK, NEK6, KCNA5, LARGE2, ZNF425, NACA2, CFAP57, SPINT1, ZNF492 and S100A6, ii) a second set of biomarkers comprising a first set of biomarkers comprising POMK, NEK6, KCNA5, LARGE2, ZNF425, NACA2, CFAP57, SPINT1, ZNF492 and S100A6, and iii) a third set of biomarkers comprising POMK, NEK6, KCNA5, LARGE2, the present invention relates to a method for identifying systemic inflammation in a subject comprising: a) a first set of biomarkers comprising: NEK6, SRPK3, TNFSF8, S100A6, NMUR1, DHFR, HIST1H4D, ZDHHC4, TRAF3 and SGMS1, or iii) a third set of biomarkers comprising: C9orf135, ZNF425, ACOT4, SPDYA, DAPP1, LY86, ZPBP2, RPL3L, UPK1B and APBB3, b) comparing the determined amounts of biomarkers from the set of biomarkers to a reference, and c) assessing systemic inflammation in the subject. In addition, the present invention generally relates to the use of the amount of said biomarker in a sample of a subject exhibiting symptoms of systemic inflammation for assessing systemic inflammation. In addition, a device and a kit for assessing systemic inflammation are contemplated.

The present invention relates to the field of liver disease, and more particularly to a method for determining the presence of chronic plus acute liver failure or for determining the risk of developing ACLF in a patient suffering from cirrhosis or a delayed early stage of ACLF. The invention also relates to a method for distinguishing patients suffering from decompensated liver cirrhosis, acute decompensated liver cirrhosis (ADC) or delayed ACLF from patients suffering from early ACLF or ACLF 1, 2, 3, a method for determining the degree of systemic inflammation and a method for determining the presence of a bacterial infection with sepsis.

The application relates to the biomedical application field of inorganic materials, and particularly relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy. The application relates to application of lanthanum carbonate in preparation of a medicine for treating hepatic encephalopathy, wherein the medicine comprises lanthanum carbonate and pharmaceutically acceptable adjuvants, and the lanthanum carbonate comprises any one or more of lanthanum carbonate hydrate and basic lanthanum carbonate. The application is based on the fact that glutamine enzyme can reduce blood ammonia, and the hepatic encephalopathy is reversed by reducing blood ammonia and systemic inflammation, the liver function is recovered by regulating inflammation, thereby helping to cure the hepatic encephalopathy, and good treatment effect is shown, so that a new candidate medicine for clinically treating the hepatic encephalopathy is provided.

This invention provides pharmaceutical compositions for inhibiting inflammation and their applications. The invention reveals that the combined use of hyaluronic acid synthesis inhibitors and ascorbate palmitate or their analogues can synergistically inhibit inflammation, significantly improving the therapeutic effect; the inflammation may include systemic inflammation and SARS-CoV-2 infection-related inflammation, including pneumonia. This invention also reveals a novel coronavirus inflammation model obtained by stimulating cells with specially isolated polynucleotides derived from the novel coronavirus genome. The model exhibits a typical inflammatory phenotype, is stable and controllable, and is intuitive and easy to observe.

This invention belongs to the field of biomedical technology, specifically relating to the application of a functional lipid in the preparation of drugs for treating systemic lupus erythematosus (SLE). Specifically, the functional lipid MLnM exhibits significant therapeutic effects in a pristane-induced SLE mouse model, effectively alleviating SLE-related clinical symptoms, improving intestinal barrier function, reducing oxidative stress levels, regulating the balance of inflammatory cytokine secretion, and reducing systemic inflammatory responses by inhibiting the expression of immune cell migration-related genes. The discovery of MLnM provides a new direction for the treatment of SLE and other autoimmune diseases.

The application discloses a kind of bone defect repair material adaptability prediction methods based on deep learning, the bone defect region and host bone region in three-dimensional CT image data are overlapped and evenly divided, and the three-dimensional visual Transformer model of multi-scale position coding is used to carry out position coding and feature extraction to multiple sub-blocks, to obtain anatomical and functional characteristics;Pathophysiological characteristics are constructed after calculating bone metabolic activity score and systemic inflammation score based on blood test data;Anatomical and functional characteristics, pathophysiological characteristics, parameter data and multi-direction multi-head cross attention layer are interacted in multiple rounds, in each round, select a modal feature as a query vector, select any modal feature in the remaining modal feature as a key vector and a value vector;The interactive features of each round are fused, and the adaptability score and risk level of bone repair material are determined by combining the attention weight in the multi-direction multi-head cross attention layer and the bone metabolic activity score.

The present disclosure relates to a methods, compositions and kits for the diagnosis and prognosis of sepsis and / or associated conditions, as well as tailoring personalized treatment regimens based on the balance between systemic inflammation and resistance state of subjects in need. The disclosed methods involve calculating the resistance (R) level and the systemic inflammation (SI) level of a subject to determine a R / SI balance score that enables classification of the subject.

A method of treating or preventing cardiovascular disease which comprises administering a therapeutically effective amount of at least one n-3 DPA-derived resolvin and / or upregulating or increasing the biosynthesis or activity of at least one n-3 DPA-derived resolvin. n-3 DPA-derived resolvins are normally regulated diurnally in the body and are linked to activation of platelets and leucocytes and formation of platelet-leukocyte aggregates. Dysfunctional regulation of n-3 DPA-derived resolvins may lead to systemic inflammation because of excessive inflammation-inducing eicosanoids, especially in the early hours of the morning. Further, decreased 5-LOX / 15-LOX expression and increased systemic adenosine concentrations are found to be associated with reduced resolvin levels and increased risk of cardiovascular disease. n-3 DPA-derived resolvins are administered to achieve maximum absorption in the early hours. Also disclosed are n-3 DPA-derived resolvins for use in the treatment or prevention of cardiovascular disease, and methods for measuring the levels of n-3 DPA-derived resolvins and / or the expression or activity of adenosine or 5-LOX / 15-LOX in biological samples obtained from a subject for assessing the subject's risk of cardiovascular disease.

This article provides compositions comprising an EV, such as an exogenous form, of a STING agonist, and methods for producing said compositions. This article also provides a method for modulating an immune response by administering a therapeutic amount of an EV, such as an exogenous form, of a STING agonist. The immune response may be an IENβ response or activation of myeloid dendritic cells (mDCs). This article further provides a method for modulating an immune response by administering an exogenous form of a STING agonist without inducing systemic inflammation.

This invention belongs to the pharmaceutical field and relates to an elastase inhibitor and its application in disease treatment. Specifically, it relates to a compound of formula (I), a pharmaceutical composition comprising compound (I), and its application in disease treatment. The compound of formula (I) of this invention has an inhibitory effect on elastase and can be used to treat or prevent diseases caused by the action of elastase, including systemic inflammatory response syndrome (SIRS) with acute lung injury (ALI) / acute respiratory distress syndrome (ARDS).

The invention discloses a preparation method and application of a novel hydrogel immunopotentiator, and belongs to the technical field of veterinary medicine. The preparation method comprises the following steps: adding a ferric trichloride solution into a hyaluronic acid solution, reacting in a stirring state, then adjusting the pH value to 5.5-7.5, and stirring to obtain hyaluronic acid hydrogel; 2 ', 3'-cGAMP with the final concentration of 0.1-800 g / mL is added into the hyaluronic acid hydrogel, and the hydrogel immunopotentiator is obtained. The invention also discloses an application of the hydrogel immunopotentiator in an alumina gel inactivated vaccine. The immunopotentiator disclosed by the invention has a 3D network structure, so that an agonist can be efficiently delivered to drainage lymph nodes in a targeted manner, systemic inflammatory reaction is avoided, and the immunopotentiation effect of the immunopotentiator is better exerted; when being used for the porcine epidemic diarrhea alumina gel inactivated vaccine, the porcine epidemic diarrhea alumina gel inactivated vaccine not only can obviously up-regulate the level of a serum neutralizing antibody, but also can effectively induce immune response of Th1 type cells and provide stronger immune protection response.

The embodiment of the application discloses a natural small molecule inhibitor targeting NLRP3 inflammasome and application thereof, and belongs to the technical field of biological medicine. Chuanxiongdiolide R11 is a phthalide dimer compound with clear stereochemistry found in traditional Chinese medicine Chuanxiong, which can target NLRP3 inflammasome, prevent the activation and assembly of the inflammasome, thereby inhibiting caspase-1 activation, GSDMD cleavage, pyroptosis and the maturation and release of IL-1beta / IL-18. The compound can be used for preparing a drug for treating NLRP3 related inflammatory diseases such as systemic inflammation and peritonitis, and has a good clinical application prospect, and provides a new idea for developing and applying NLRP3 inhibitors in clinic.

Disclosed are therapeutic compositions of matter for use in regulation of local and systemic inflammation and reduction of oxidative stress to enable discovery and development of more effective pharmaceutical agents, organic compounds, and other medicinal formulations.

This formulation can be applied to Parkinson's disease patients to improve the stability of levodopa (L-DOPA) in the body and its availability to the central nervous system. This formula can regulate the gut microbiota, strengthen the intestinal barrier function, reduce systemic inflammation and oxidative pressure, further improve motor and non-motor dysfunction, and delay or reduce the occurrence of side effects of long-term L-DOPA treatment, such as dysregulation. [Solution] The present invention discloses a probiotic cocktail medical food formulation that comprises at least one probiotic and can selectively combine one or more amino acids.

The invention belongs to the technical field of biological medicines, and particularly relates to application of fenerenone in preparation of a medicine for treating polycystic ovarian syndrome. According to the invention, the fenerenone is used as a high-selectivity non-steroidal salt corticoid receptor antagonist to regulate and control local and systemic inflammatory response of ovary, oxidative stress state, insulin signal pathway and serum hormone level, so that the core pathological mechanism of polycystic ovarian syndrome is intervened.

The invention discloses a phase separation mediated nano trap for removing extracellular free DNA (Deoxyribonucleic Acid) as well as a preparation method and application thereof, and relates to the technical field of medical nano biological materials. The nano trap takes hollow mesoporous cerium dioxide as a core, DNA degrading enzyme is loaded in the nano trap through a coordinate bond, and a cationic polymer layer is modified on the surface of the nano trap, so that the nano trap has positive zeta potential. The structure can be used as a nucleation center to efficiently capture negatively charged cfDNA; the cfDNA is mediated to generate liquid-liquid phase separation to form a stable aggregate, and then the cfDNA is subjected to in-situ degradation through a loaded enzyme. The invention further discloses a construction method of the nano trap and application of the nano trap in preparation of drugs for treating or preventing systemic inflammatory response syndromes (such as septicopyemia) mediated by abnormal cfDNA level rise. The nano trap provided by the invention has the advantages of high cfDNA removal efficiency, innovative mechanism, synergistic effects of oxidation resistance and bacteria resistance and the like, and provides an effective new way for treatment of related diseases.

A combination of medications and medication doses is disclosed whereby age-related changes in systemic inflammation, cancer risk, heart disease risk, CD38 expression, hair color, thymotrophic hormones, immune cell populations, the CD4 / CD8 cell ratio, bone marrow density, thymus structure, kidney function, and epigenetic age can be reversed in humans. Surprisingly, agents that accelerate the growth of cells reduce cancer risk, agents that intensify immune responses attenuate age-related inflammation, agents with no prior connection to hair color reverse age-related hair whitening, and a combination of agents that induces IGF-1, a hormone previously thought to drive systemic aging, results in a reversal of systemic aging as documented by an epigenetic clock. Medication combinations useful in the present invention include human growth hormone (GH) or GH releasers, dehydroepiandrosterone (DHEA), and metformin.

The invention belongs to the technical field of functional foods and medicines, and particularly discloses application of L-selenium methyl selenocysteine in preparation of a product for targeted regulation of intestinal flora to relieve chemotherapy immune injury. The target regulation is realized by specifically improving the relative abundance of the beneficial bacteria, namely, Bacteroides acdifaciens, in the intestinal tracts of the subject, so that the relative abundance of the beneficial bacteria, namely the Bacteroides acdifaciens, in the intestinal tracts of the subject is improved. Systematic contrast experiments prove that under the condition of equal selenium content, the selenium-enriched milk powder strengthened by taking L-selenium methyl selenocysteine as a unique selenium source has the effect obviously superior to that of contrast milk powder strengthened by selenium-enriched yeast or sodium selenite in the aspect of relieving immunosuppression, intestinal injury and systemic inflammation caused by cyclophosphamide. The core mechanism of the L-selenium methyl selenocysteine is that the L-selenium methyl selenocysteine can be used for efficiently and specifically enriching Bacteroides acdifaciens, and the L-selenium methyl selenocysteine can be used for efficiently and specifically enriching Bacteroides acdifaciens. Based on the discovery, the invention correspondingly provides a selenium-enriched milk powder product with definite targeting property and excellent effects, and a brand new efficient solution is provided for chemotherapy auxiliary nutrition support of tumor patients.

The application belongs to the technical field of medicine preparation, and particularly relates to application of cellulose nanofiber in preparation of medicine for preventing or treating gestational diabetes mellitus. In the application, the CNF has significant adsorption capacity for micro / nano plastic due to its high specific surface area and unique surface characteristics. Moreover, the CNF intervention can effectively reduce the deposition of microplastics in organs such as liver and placenta, and reduce the trans-barrier transport and biological toxicity of harmful particles from the source. In addition, the CNF can effectively repair the intestinal barrier damage caused by microplastic exposure or high-fat diet, and reduce the systemic inflammation level. Furthermore, the CNF intervention can significantly reduce the fasting blood glucose of the microplastic exposure model mouse during pregnancy, improve the area under the curve (AUC) of insulin tolerance test (ITT) and oral glucose tolerance test (OGTT), and restore the insulin sensitivity.

The application belongs to the technical field of biological medicine, and particularly relates to application of (E)-BCI hydrochloride in preparation of a medicine for treating sepsis. The application provides application of (E)-BCI hydrochloride in preparation of the medicine for treating sepsis. (E)-BCI hydrochloride regulates a DRD1 gene through targeting, quiets an interferon stimulation storm, reduces abnormal activation of astrocytes, reduces a level of an inflammatory factor, improves expression of a nerve activity gene, and provides a non-antibiotic dependent medicine for sepsis treatment from a new target point of regulating inflammation and immune balance, and is particularly suitable for systemic inflammatory response syndrome caused by various causes such as infection, operation and trauma, and has a wide clinical application prospect.

The invention provides an application of a small molecule compound in preparation of an anti-aging product, and the small molecule compound can effectively intervene in an aging-related pathological process, significantly relieve systemic inflammation existing in an aging body, improve motor function decline caused by aging, and significantly enhance muscle function, coordination and endurance. And the overall exercise ability is improved. In addition, the small molecule compound can also significantly enhance the anti-infection ability of an elderly individual to bacteria, effectively relieve excessive inflammatory response and tissue pathological damage caused by infection and break vicious circle of infection acceleration function decline, and the effect of the small molecule compound is achieved by inhibiting overexpression of an STAT1 signal. The invention provides a new strategy with multiple beneficial effects of improving senescence-related chronic inflammation, motor function decline and bad outcome after infection, and provides a new technical choice for developing intervention means for senile co-diseases.

The invention relates to application of a composition in a product for improving intestinal inflammation complicated by chronic kidney diseases, and belongs to the technical field of biological medicines. The composition provided by the invention consists of morinda officinalis polysaccharide, synanthrin and water, the synergistic effect of the two polysaccharides can be exerted, the physical and chemical properties and biological activity of the morinda officinalis-synanthrin composition can be improved, the intestinal barrier can be remarkably repaired, the systemic inflammation level can be reduced, and the composition has a remarkable effect on treating intestinal inflammation complicated by chronic kidney diseases.

The invention provides assays and methods for detecting and monitoring systemic inflammation. Particularly, the invention in embodiments thereof relates to the use of urinary biomarkers for non-invasive determination of the level of inflammation.

Disclosed herein are compounds that disrupt the protein-protein interaction between Muncl3-4 and syntaxin 7, methods of discovering such compounds, and methods of their use to treat systemic inflammation.